✨ Free AI Report
Lexicon Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Lexicon Pharmaceuticals, Inc.
Company Research

Lexicon Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and commercializing precision medicines using Nobel Prize-winning gene science technology. The company is advancing a pipeline of late-stag...

Analyst-debate audio for Lexicon Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Lexicon Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
6/ 10Solid

Cyborg Score thesis

Risk-reward turnaround play dependent on successful Phase 3 completion and regulatory approvals for pilavapadin and sotagliflozin...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Pharmaceutical Development
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Lexicon Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Lexicon Pharmaceuticals, Inc. Overview

Pro stress-test →

Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and commercializing precision medicines using Nobel Prize-winning gene science technology. The company is advancing a pipeline of late-stage cardiometabolic and neuroscience therapies, including INPEFA (commercialized), pilavapadin, LX9851, and sotagliflozin, with significant revenue growth achieved in 2024.

Strategic Profile

Pro stress-test →

Lexicon leverages proprietary gene science platforms to develop targeted therapeutics in high-demand markets including heart failure, type 2 diabetes, chronic kidney disease, and obesity. Strategic partnerships with Novo Nordisk, Viatris, and Bristol-Myers Squibb provide commercialization capabilities and capital support, positioning the company as a potential turnaround story despite historical challenges.

Competitive Landscape

Pro stress-test →

Lexicon competes in crowded cardiometabolic and neuroscience markets against established pharma and well-funded biotech. Key competitors include Sangamo Therapeutics, Apellis Pharmaceuticals, Iovance Biotherapeutics, and others developing similar indications. Differentiation through proprietary gene science and strategic partnerships with larger pharma (Novo Nordisk, Bristol-Myers Squibb) provides distribution and credibility advantages.

Industry Context

Lexicon Pharmaceuticals, Inc. operates in Biopharmaceutical / Pharmaceutical Development.

Key facts

Founded: 1995 · Headquarters: The Woodlands, Texas, USA · Revenue: $31.08M (2024)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Lexicon Pharmaceuticals, Inc..

  • Revenue surged 2481% to $31.08M in 2024, driven by INPEFA commercialization and partnerships, signaling successful transition from development-stage company
  • Three late-stage assets with high-reward potential: pilavapadin (neuropathic pain, obesity), sotagliflozin (heart failure, type 1 diabetes, HCM), and LX9851 (partnered with Novo Nordisk for obesity indication)
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Lexicon announced closing of underwritten public offering for capital raise
  • January 2026Presented at J.P. Morgan Healthcare Conference; SONATA-HCM enrollment on track for 2026 completion; $10M milestone payment from Novo Nordisk
  • +2 moreTrack every material event for Lexicon Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Lexicon Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

SGLT2 Inhibitors & GLP-1 AgonistsEstablished therapies in cardio-metabolic space→Gene Therapy PlatformsCompeting precision medicine approaches→Rare Disease TherapeuticsLate-stage biotech competitors in specialized indications→

Compare Lexicon Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Lexicon Pharmaceuticals, Inc. operates in Biopharmaceutical / Pharmaceutical Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Pharmaceutical Development research →
NEW · MCP server

Ask your AI assistant about Lexicon Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Lexicon Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Lexicon Pharmaceuticals, Inc. do this quarter?”
“Is Lexicon Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Lexicon Pharmaceuticals, Inc. do?+
Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering and commercializing precision medicines using Nobel Prize-winning gene science technology. The company is advancing a pipeline of late-stag...
What is Lexicon Pharmaceuticals, Inc.'s Cyborg Score?+
Lexicon Pharmaceuticals, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Lexicon Pharmaceuticals, Inc.'s main competitors?+
Named competitors include SGLT2 Inhibitors & GLP-1 Agonists, Gene Therapy Platforms, Rare Disease Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Lexicon Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Lexicon Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Lexicon Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score